Minimally invasivE versus open total GAstrectomy (MEGA): study protocol for a multicentre randomised controlled trial (DRKS00025765)

Felix Nickel,1 Alexander Studier-Fischer,1 David Hausmann,1,1 Rosa Klotz,1,2 Sophia Lara Vogel-Adigozalov,1,1,2 Solveig Tenckhoff,1,1,2 Christina Klose,3 Manuel Feisst,4 Samuel Zimmermann,4 Benjamin Babic,5 Felix Berlt,6 Christiane Bruns,7 Ines Gockel,7 Sandra Grat,8 Peter Grimminger,6 Christian A Gutschow,9 Jens Hoeppner,10 Kaja Ludwig,11 Lutz Mirow,12 Stefan Mönig,13 Daniel Reim,14 Florian Seyfried,15 Daniel Stange,16 Adrian Billete,1 Henrik Nienhüser,1 Pascal Probst,5,17 Thomas Schmidt,5 Beat Peter Müller-Stich1

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Minimally invasivE versus open total GAstrectomy (MEGA) is the first Western multicentre randomised controlled trial to specifically compare open gastrectomy with minimally invasive gastrectomy in terms of postoperative morbidity using the Comprehensive Complication Index (CCI).
⇒ Usage of the CCI as a comprehensive outcome measure allows for objective comparisons with other trials.
⇒ Differentiation between robotic and laparoscopic gastrectomy will be made in the explorative subgroup analysis only.
⇒ High levels of standardisation, intraoperative photo documentation, well-powered group sizes and risk-based monitoring by the Study Center of the German Society of Surgery will guarantee objective data acquisition, increase patients’ adherence to the protocol, and ultimately, lead to exceptional data quality.

INTRODUCTION
Gastric cancer is the sixth most common tumour disease in the world and causes the second most deaths.1 In 2018, approximately one million patients worldwide and approximately 15 000 patients in Germany were diagnosed with gastric cancer, of which an average of 76% die from the disease.1 Gastric cancer causes one of the highest oncological disease burdens as measured by lost disability-adjusted life-years (DALYs). This fact
highlights the aggressiveness of the disease. Age-adjusted DALY rates per 100,000 reach 241 for men and 146 for women, ranking 4th after liver, lung and breast cancer.2,3

Currently, the only therapy that offers a chance of cure is gastrectomy, with a 5-year survival rate of 20%–30% and postoperative morbidity and mortality as high as 63%1 and 11%,5–10 even at experienced centres.2,4–18 Therefore, there is a great need to identify the optimal surgical approach using evidence from multicentre data in order to improve oncological outcome and to decrease postoperative complications.

The current gold standard is open gastrectomy (OG) with D2 lymphadenectomy (LAD) (online supplemental appendix 2), but its highly invasive nature leads to potentially high complication rates, especially in elderly and obese patients. These frequent postoperative complications result in higher mortality, lower QoL, a longer hospital stay and thus a higher burden on the healthcare system.6,10 In other fields of visceral surgery, such as appendectomy, cholecystectomy, obesity surgery and esophagectomy, minimally invasive surgery has already replaced the open approach as the standard of care.7,20–22 Several randomised controlled trials (RCTs) have demonstrated reduced postoperative complications following minimally invasive surgery compared with the open approach. This finding is due to the procedure’s resulting smaller wounds, reduced operative trauma, lower blood loss, shorter hospital stay and faster rehabilitation time.22–24

Postoperative complications, however, are not only important for the immediate postoperative course, which is usually secondary in relevance, but can also affect long-term oncological outcome.25–27 In a study of 432 patients with curative gastrectomy and D2 LAD for treatment of gastric cancer, the occurrence of postoperative in-hospital complications was an independent predictor of worse 5-year survival (22% vs 40%). This can be perceived as an indication that postoperative complications may lead to higher mortality in the long term.28 Therefore, the trend towards favouring minimally invasive gastrectomy (MIG) for gastric cancer is increasing.

Methods and analysis

Setting
The Minimally invasivE versus open total GAstrectomy (MEGA) trial is a prospective randomised, controlled, non-blinded, two-armed multicentre surgical superiority trial with a confirmatory character. It includes 14 surgical centres in Germany and Switzerland and is coordinated by the Department of General, Visceral and Transplantation Surgery at Heidelberg University Hospital, in Germany. Recruitment is planned for two consecutive years. The study protocol was accepted by the Independent Ethics Committee of the Medical Faculty, University of Heidelberg (registration number S-816/2021) prior to recruitment. The trial was registered at DRKS under the registration number DRKS00025765 on 22 December 2021.29 No secondary identifying numbers such as a Universal Trial Number have been assigned. Recommendations of the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) checklist were followed.30

Patient recruitment
Recruitment is planned to take place at 14 surgical centres in Germany and Switzerland. Certain eligibility criteria have to be met by the participating centres and surgeons in order to eliminate bias from inexperience or learning curves. Therefore, hospitals need to have a case load of ≥20 gastrectomies per year, and every trial surgeon has to provide evidence of at least 20 previously performed surgeries of the respective surgical procedure/s, he or she wants to contribute (OG, laparoscopic gastrectomy (LAG) or robotic-assisted gastrectomy (RAG)). Eligible patients will be screened consecutively to eliminate selection bias and will receive diagnostic staging laparoscopy prior to randomisation.

Inclusion criteria
► Age between 18 and 84 years.
► Planned total gastrectomy after first diagnosis of gastric carcinoma.
► Ability of patient to understand character and consequences of the trial.
► Written informed consent.

Exclusion criteria
► ECOG performance status ≥2.
► Planned extended gastrectomy or less than total gastrectomy (eg, adenocarcinoma of the esophago-gastric junction (AEG) I and AEG II, or distal gastric tumours of an intestinal subtype).
► Previous gastric surgery or extensive adhesions seriously complicating MIG.
► Other active oncological disease or history of cancer limiting prognosis in comparison to the gastric cancer.
► Emergency setting.
► Language barriers rendering the patient unable to fill out patient-reported outcome questionnaires.
► Participation in another intervention trial that might interfere with the intervention and/or outcome of this trial.
► Pregnancy.

Exclusion criteria previously or during staging laparoscopy:
► T4.
► M1.

Neoadjuvant chemotherapy does explicitly not contribute to inclusion or exclusion criteria, but will of course be monitored. Inclusion takes place after the staging laparoscopy, and patients will be randomised to the intervention arm (MIG) or the control arm (OG) (figure 1).

Trial duration and schedule
Recruitment is planned to take 24 months. The duration of the trial for each patient is expected to be 1
month for the primary endpoint and 60 months for the secondary endpoints with long-term follow-up. Consequently, the duration of data collection is expected to be 25 months for the primary endpoint and 84 months for the secondary endpoints (first-patient-in (FPI) to last-patient-out (LPO)). FPI is planned for September 2022 and last-patient-in is planned for September 2024. LPO is consequently planned for September 2029. Trial analysis will take an additional 6 months. The actual overall duration or recruitment time may differ. Recruitment is planned to be active until both arms contain at least 80 patients in the intention-to-treat (ITT) dataset.

Trial visits
Patients will be monitored intraoperatively, on postoperative days (POD) 1, 3 and 5, and on the day of discharge. Follow-up will be conducted on POD 30, 90 and after postoperative months 6, 12, 24, 36, 48 and 60 (table 1). Demographic and baseline clinical data, intraoperative findings and postoperative results will be recorded. During the follow-up, patients will complete established and validated questionnaires. To enhance participant retention and to avoid lost to follow-up, patients will be contacted for the completion of questionnaires and to collect missing data. Informed consent will be obtained and trial data will be collected by trained assessors using electronic case report forms (eCRFs).

Primary endpoint
The primary endpoint will be postoperative morbidity measured using the Comprehensive Complication Index (CCI) until POD 30. Usage of this index will enable a comparison of the severity and individual burden of postoperative complications with results from other trials. Postoperative morbidity is defined as any deviation from the normal postoperative course according to the Clavien-Dindo classification. This includes anastomotic insufficiency or loss of anastomotic integrity verified by either CT scan with detection of contrast agent external to the anastomosis, endoscopy, or the detection of methylene blue in a drain following oral intake.

Secondary endpoints
Secondary endpoints can be separated into short-term clinical and oncological endpoints as well as long-term clinical and oncological endpoints (at 5-year follow-up, as measured from the date of surgery) and can be found in table 1. Hyperspectral imaging of the surgical site intraoperatively (visit 3) will be performed in Heidelberg only.

Standardised therapy and trial interventions
Control: Total OG with D2/D2+LAD.

Intervention
Total MIG with D2/D2+LAD either as LAG or RAG. A minilaparotomy or a Pfannenstiel incision (<8 cm incision in both the skin and fascia) may be performed for specimen removal.

Modified cardia-preserving total gastrectomy (preservation of gastro-oesophageal junction) can also be accepted, but only if the short gastric vessels are dissected as well, and if LAD is the same as for total gastrectomy. Besides the open or minimally invasive approach, the remaining treatment is identical in

Figure 1  Trial design flow chart. *Intraoperative conversion from MIG to OG, for example, due to bleeding. **Lost to follow-up over 30 POD. MIG, minimally invasive gastrectomy; OG, open gastrectomy; POD, postoperative day; POM, postoperative month.
<table>
<thead>
<tr>
<th>Activity and documentation</th>
<th>Visit 1 (screening)</th>
<th>Visit 2 (laparosc.)</th>
<th>Visit 3 (surgery)</th>
<th>Visits 4–6 (POD 1, 3, 5)</th>
<th>Visit 7 (discharge)</th>
<th>Visits 8–9 (POD 30, 90)</th>
<th>Visits 10–15 (POM 6, 12, 24, 36, 48, 60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion and exclusion criteria</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history and preoperative assessment*</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomisation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical and anaesthetic documentation†</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postoperative morbidity measured with CCI (primary endpoint) until POD 30</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X (V6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biological specimen retrieval</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDTA blood samples</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formalin and paraffin tissue samples</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Short-term clinical endpoints**

| Postoperative morbidity measured with the CCI until POD 90       | X                   | X                   | X                  | X                      |                     |                        |                                         |
| Major complications (Clavien-Dindo ≥3) until POD 90              | X                   | X                   | X                  | X                      |                     |                        |                                         |
| Conversion rate                                                  | X                   |                     |                    |                        |                     |                        |                                         |
| Operation time                                                   | X                   |                     |                    |                        |                     |                        |                                         |
| Blood loss                                                       | X                   |                     |                    |                        |                     |                        |                                         |
| Length of stay in the ICU                                        | X                   |                     |                    |                        |                     |                        |                                         |
| Length of hospital stay                                          |                     |                     |                    |                        | X                   |                        |                                         |
| Pain and postoperative analgesic required                        | X                   |                     |                    |                        |                     |                        |                                         |
| Laboratory parameters (CRP, leucocytes)                          | X                   | X                   |                    |                        |                     |                        |                                         |
| Mobilisation of the patient                                      | X                   |                     |                    |                        |                     |                        |                                         |
| Quality of the patient’s recovery (QoR-15)                       | X (V6)              |                     |                    |                        |                     |                        |                                         |
| Quality of life (EUROQOL EQ-5D-5L, EORTC QLQ-C30, EORTC QLQ-STO22, ADL) | X                   | X                   | X                  | X                      |                     |                        |                                         |
| Adherence to a fast-track gastrectomy SOP                        | X                   | X                   | X                  | X                      |                     |                        |                                         |
| Objective evaluation of anastomoses                               | X                   |                     |                    |                        |                     |                        |                                         |
| First bowl function                                              |                     | X                   |                    |                        |                     |                        |                                         |
| Wound healing deficits                                           | X                   | X                   | X                  | X (V8)                |                     |                        |                                         |
| Vegetative function‡                                              | X                   |                     |                    |                        | X                   | X                      |                                         |
| Necessity of interventions due to complications                  | X                   | X                   | X                  | X                      |                     |                        |                                         |
| Oncological short-term data                                       |                     |                     |                    |                        |                     |                        |                                         |

*Continued*
both groups. Any other form of gastrectomy, explicitly conventional subtotal gastrectomy (preserved short gastric vessels and limited LAD of station 2 and 4sa), extended gastrectomy and distal gastrectomy with Billroth I or II reconstruction are not allowed. Reconstruction can be of any form including Roux-Y reconstruction, interposition or pouch reconstruction. Any other step of the procedure such as antibiotic prophylaxis, placement of abdominal drains and closure of the abdominal wall can be performed according to in-house standards. D2 LAD is defined according to the Japanese classification, with stations 1, 2, 3a, 3b, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d and 12a obligatory for the MEGA trial (figure 2). Station 10 is optional. Incomplete LAD is not allowed and has to be documented as a protocol deviation.

Removal of further stations (8b, 12b, 12p, 13, 14v, 14a, 15, 16a1, 16a2, 16b1, 16b2, 17, 18, 19, 20, 110, 111 and 112) is allowed when deemed appropriate, for example, in case of assumed tumour invasion, and has to be documented as D2+. 

<table>
<thead>
<tr>
<th>Activity and documentation</th>
<th>Visit 1 (screening)</th>
<th>Visit 2 (laparosc.)</th>
<th>Visit 3 (surgery)</th>
<th>Visits 4–6 (POD 1, 3, 5)</th>
<th>Visit 7 (discharge)</th>
<th>Visits 8–9 (POD 30, 90)</th>
<th>Visits 10–15 (POM 6, 12, 24, 36, 48, 60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of lymph nodes removed and of tumour-positive lymph nodes</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No of R0 resections</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development of tumour markers (CA 125, CA 19–9, CA 72–4, CEA)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumour histopathology§</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-term clinical data (5 year follow-up)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Changes of body weight</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life (EUROQOL EQ-5D-5L, EORTC QLQ-C30, EORTC QLQ-STO22, ADL, BIS)</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Incidence of incisional hernias</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X (V13)</td>
</tr>
<tr>
<td>Incidence of reoperations</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence of stenosis</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cosmetic results and scar satisfaction (BIS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X (V13)</td>
</tr>
<tr>
<td>Oncological long-term data (5-year follow-up)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncological treatment (adjuvant and consecutive therapy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X (V9)</td>
</tr>
<tr>
<td>Disease-free survival recurrence-free survival, RFS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(V9)</td>
</tr>
<tr>
<td>Local recurrence</td>
<td>X (V9)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X (V9)</td>
</tr>
<tr>
<td>RFS</td>
<td>X (V9)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X (V9)</td>
</tr>
<tr>
<td>Progression-free survival</td>
<td>X (V9)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X (V9)</td>
</tr>
<tr>
<td>Time to progression</td>
<td>X (V9)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X (V9)</td>
</tr>
<tr>
<td>Overall survival</td>
<td>X (V9)</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X (V9)</td>
</tr>
</tbody>
</table>

*Includes body mass index, ASA status, preoperative oncological status, prior surgical treatment, drug use and comorbidities.
†Includes surgical documentation (surgeons, procedures, complications, drains) and anaesthesiology documentation.
‡Includes dysphagia, reflux and dumping syndromes.
§Includes entity, TNM, grading and resection status. 
ADLs, activities of daily living; ASA, American Society of Anesthesiologists; BIS, Body Image Scale; CA, carbohydrate antigen; CCI, Comprehensive Complication Index; CEA, carcinoembryonic antigen; ECOG, Eastern Co-operative Oncology Group; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; EORTC QLQ-STO22, EORTC Quality of Life Questionnaire for Gastric Cancer; EUROQOL EQ-5D-5L, EuroQol Group Questionnaire for Quality of Life with 5 dimensions and 5 levels; ICU, intensive care unit; POD, postoperative day; POM, postoperative month; GoR-15, Quality of Recovery 15; SOP, standard operating procedure.
Postoperative management
Postoperative management should be performed in a fast-track approach with short durations until patient mobilisation, drainage removal and first oralisation of food. The patient should be extubated immediately after surgery and transferred to a normal ward, if possible. Further specifications for the postoperative course will be outlined in the provided standard operating procedure (SOP) for fast-track gastrectomy. The last in-hospital trial visit takes place on the day of discharge. Subsequent trial visits will be conducted via telephone. These will be questionnaire-based and focus on CCI (until POD 90), QoL and oncological outcome.

Randomisation and blinding
In order to ensure equal distribution of patient characteristics between both trial arms, randomisation will be performed using a web-based randomisation tool (www.randomizer.at). Randomisation will take place following diagnostic laparoscopy (visit 2). The allocation pattern is masked, block-randomised with variable block length, and stratified across centres. Due to the pragmatic character of the trial, blinding of the surgeon is not feasible.

Quality assurance and quality management
Clinical data monitoring
Clinical monitoring will be performed by independent monitors at the Study Center of the German Society of Surgery. The monitoring strategy will comprise a combination of centralised and onsite monitoring and will be described in a trial specific monitoring plan. To confirm site selection, presudy visits will be performed. On-site monitoring will focus on patient informed consent, safety and surgical procedures as well as the correct recording and documentation of the primary and secondary endpoints by source data verification (SDV).

Surgical quality control
Several steps are necessary to ensure and evaluate surgical quality:
1. Trial surgeons must have performed 20 surgeries in the respective approach (OG, LAG or RAG), depending on the trial arm they will contribute to.
2. Each trial surgeon must provide photographic or video documentation of a former procedure.
3. Each trial surgeon has to provide photographic or video documentation of the trial procedures, which will be assessed by an expert. This photographic or video documentation is defined as follows:
   - Lymph node station 7 (left gastric artery) after dissection.
   - Lymph node station 8 a (common hepatic artery) after dissection.
   - Lymph node station 9 (coeliac artery) after dissection.
   - Lymph node station 10 (splenic hilum) after dissection.
   - Lymph node station 11p (proximal splenic artery) after dissection.

Figure 2  Schematic lymphadenectomy. Stations for lymphadenectomy (LAD) as required for total gastrectomy according to the cited Japanese classification. Schemes are separated into D1 LAD, D2 LAD and further lymph node stations.
Lymph node station 11d (distal splenic artery) after dissection.
Lymph node station 12a (hepatoduodenal ligament along the hepatic artery) after dissection.
Duodenal stump.
Incision for specimen retrieval in MIG.

Assessment of safety
Since the primary endpoint is postoperative complications as measured by the CCI, adverse (AE) and serious AEs (SAE) are already captured and no additional safety analysis will be performed (table 2).

Data management
The Institute of Medical Biometry (IMBI) is responsible for data management within this trial. An eCRF will be used for data collection. To assure safe and secure data use and storage, data transmission is encrypted with secure socket layer technology. Only authorised users are able to enter or edit data, and access is further restricted to data of the patients in that user’s respective centre only. All changes to data are logged with a computerised timestamp in an audit trail. All data will be pseudonymised. To guarantee high data quality, data validation rules will be defined in a data validation plan. Completeness, validity and plausibility of data will be checked at the time of data entry (edit checks) and using validating programmes, which will generate queries. If no further corrections are to be made in the database, eCRF data will be locked. Data will finally be downloaded and used for statistical analysis. All data management procedures will be conducted according to written defined SOPs of the IMBI that guarantee efficient conduct in compliance with Good Clinical Practice. At the end of the study, the data will be transformed into different data formats (eg, csv-files) for archiving and to ensure that it can be reused.

Statistical methods
Sample size
The sample size calculation is based on the primary endpoint ‘postoperative morbidity as measured with the CCI until POD 30’.

\[
\text{Effect size} = d = 0.5
\]

A decrease of the CCI by 10 points between OG and MIG is considered relevant by patients and clinicians, and a conservative SD of 20 is assumed leading to an effect size of \(d=0.5\). Based on a t-test with a two-sided significance level of \(\alpha=0.05\), a sample size of \(n=128\) patients (64 per group) has to be recruited to achieve a power of 80%. The primary endpoint will be analysed with a linear mixed regression model, which leads to equal or even increased power when compared with a two-sided t-test. To compensate for drop-outs and patients lost to follow-up, a further 20% of patients will be randomised, leading to a total sample size of \(n=160\) (80 per group; 80×0.8 = 64.8). The number of patients to be screened (\(n=400\) to be assessed for eligibility; 400×0.5×0.8=160) was calculated with an assumed 50% participation rate and an exclusion rate of 20%.

Randomised and allocated (\(n=160\); 80 per group).
ITT dataset (\(n=160\); 80 per group).
Per-protocol dataset (\(n=136\); 72 and 64).

Statistical analysis
For the examination of the primary endpoint ‘postoperative morbidity measured with the CCI until POD 30,’ the hypotheses to be assessed in the primary analysis are as follows: \(H_0: \mu_1 = \mu_2\) vs \(H_1: \mu_1 \neq \mu_2\), where \(\mu_1\) and \(\mu_2\) denote the mean CCI in the control and intervention groups, respectively. The significance level is set to a two-sided \(\alpha=0.05\). Therefore, the primary endpoint will be examined using a linear mixed model adjusting for the variables age and treatment group, as well as the surgical centre as a random effect (due to the stratified randomisation and relatively large number of centres in relation to the sample size, inclusion of centre as a random effect is recommended). Details of the primary model (eg, handling of missing values, sensitivity analyses) will be fully described in the statistical analysis plan.

The number of patients included in the primary analysis is determined as the full analysis set. Patients will be analysed in the group they were randomised to (converted patients remain in their group). This reflects an analysis according to the ITT principle. Specific events (eg, death) that can occur after randomisation will be handled within the primary endpoint definition, reflecting a composite strategy (according to the ICH E9 (R1) addendum). Other post-randomisation events will not be considered. This choice reflects our treatment policy approach.

In general, for the full analysis set, all baseline values and secondary outcomes will be evaluated descriptively, with \(p\) values reported alongside 95% CIs for the corresponding effects. Furthermore, secondary endpoints will be evaluated descriptively, using appropriate regression

<table>
<thead>
<tr>
<th>Table 2 Grading of adverse events (AEs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clavien-Dindo AE</td>
</tr>
<tr>
<td>Grade I complication AE</td>
</tr>
<tr>
<td>Grade II complication</td>
</tr>
<tr>
<td>Grade III complication</td>
</tr>
<tr>
<td>Grade IV complication SAE</td>
</tr>
<tr>
<td>Grade V complication</td>
</tr>
</tbody>
</table>

models. Time-to-event endpoints will be evaluated by methods of survival analysis including Kaplan-Meier methods and Cox proportional hazards models. In addition, subgroup analyses (including age, gender, tumour stage, tumour grade, histological tumour type, linear vs circular stapler for proximal anastomosis, linear vs hand-sewn for distal anastomosis, type of retrieval incision and intraoperative conversion) will be carried out. A detailed and comprehensive statistical analysis plan will be written shortly after the first patient is recruited. All analyses will be performed using SAS V.9.4 or higher.

DISCUSSION

We performed a systematic literature search prior to planning this trial and identified 974 publications. Of those, 17 RCTs comparing LAG with OG and 2 RCTs comparing RAG with OG were found to be relevant. The studies showed comparable oncological and short-term postoperative outcomes for MIG and OG. However, 16 of the 19 studies were conducted in China, Korea and Japan. These countries have a significantly higher incidence of gastric cancer, which consequently leads to significantly higher surgical volume and expertise among the participating centres. In addition, the body constitution of Asian patients is often different from that of Western patients, which limits the direct transferability of study results. Also, the incidence of gastric cancer is lower in Western populations and advanced disease stages are more frequently detected, because screening is less common. Therefore, it is unclear whether these results would be reproducible in a Western population.

Currently, there have only been three non-Asian RCTs directly comparing LAG and OG. The first RCT, by Hüscher et al, focused exclusively on distal gastrectomy, did not define any specific primary or secondary endpoints, and included a total of 59 patients. Due to the missing differentiation between primary and secondary endpoints, the trial can be perceived as methodically limited and was most likely underpowered. However, no significant difference was found in perioperative outcome, oncological outcome or mortality (morbidity rates: 26.7% (LAG) and 27.6% (OG), lymph nodes harvested: 30.0±14.9 (LAG) and 33.4±17.4 (OG), operative mortality rates: 3.3% (LG) and 6.7% (OG), 5-year survival rate: 54.8% (LAG) and 55.7% (OG)).

The only two currently existing relevant Western multicentre RCTs comparing open versus minimally invasive oncological total gastrectomy are the laparoscopic versus open gastrectomy for gastric cancer (LOGICA) trial and the STOMACH trial, which were both published in 2021.

The LOGICA trial is a non-blinded, multicentre superiority trial with 227 patients with postoperative hospital stay as the primary endpoint. The study identified significant differences regarding blood loss (150 mL (LAG) and 300 mL (OG), p<0.001) and operating time (216 min (LAG) and 182 min (OG), p<0.001), but no significant differences in hospital stay (p=0.34), postoperative complications (44% (LAG) and 42% (OG), p=0.91), in-hospital mortality (4% (LAG) and 7% (OG), p=0.40), R0 resections (95% (LAG) and 95% (OG), p=1.00), median lymph node yield (29 (LAG) and 29 (OG), p=0.49), 1-year overall survival (76% (LAG) and 78% (OG), p=0.74), and health-related QoL (+1.5 (LAG) and +3.6 (OG) on a 1–100 scale).

The STOMACH trial is an observer-blinded, multicentre, non-inferiority trial with 96 patients following neoadjuvant chemotherapy with quality of oncological resection (radicality of surgery and number of retrieved lymph nodes) as the primary endpoint. Mean number of resected lymph nodes (41.7±16.1 (LAG) and 43.4±17.3 (OG), p=0.612), number of R0 resections (44/47 (LAG) and 48/49 (OG), p=0.617), 1-year survival (85.5% (LAG) and 90.4% (OG), p=0.701), postoperative complications (16/47 (LAG) and 21/49 (OG), p=0.408), and postoperative QoL (measured with EQ-5D, EORTC-QLQ-C30, and EORTC-QLQ-STO22) were not significantly different.

In a regular setting with a diagnosed carcinoma, patients should usually be advised to make their decision for or against a certain treatment option with regard to a combination of highest expected overall survival and simultaneous conservation of long-term QoL. Short-term postoperative complications should only be treated as secondary deciding factors. However, if postoperative complications might impair long-term QoL or even overall survival, they become equally relevant. In general, postoperative complications can have negative effects on QoL or overall survival; however, this is much more the case for gastric cancer, as time to continuation of perioperative chemotherapy can be prolonged and the prognosis therefore worsened.

The STOMACH trial provides evidence that MIG is non-inferior to OG in terms of oncological quality of resection, which is a necessary requirement for the MEGA trial, as postoperative morbidity and complications can only be decisive factors in the case of oncological non-inferiority for an oncological resection with curative intent.

While both the STOMACH and LOGICA trials suggest that postoperative complications might not be significantly different between both groups, a premature confirmative statement must be avoided as complications have only been investigated as secondary endpoints so far. Consequently, a multicentre RCT comparing total MIG and OG for gastric cancer in terms of postoperative complications is needed to decide whether MIG should be established as the new standard treatment for resectable gastric cancer in Europe.

The MEGA trial has strict quality control measures and will be conducted in line with all relevant guidelines. Therefore, it will provide the highest level of evidence on this very relevant clinical research question.
ETHICS AND DISSEMINATION
The MEGA trial conforms to the Declaration of Helsinki. The Independent Ethics Committee of the Medical Faculty, University of Heidelberg, approved the MEGA trial protocol (registration number S-816/2021). For other trial centres, recruitment will only be initiated after receiving approval from their respective local ethics committees. Online supplemental additional file 1 provides the SPIRIT checklist for intervention trials.

Study objectives and procedures will be communicated clearly to all qualifying patients and written informed consent will be obtained from those who agree to participate. Results will be presented at scientific meetings and published in international peer-reviewed journals. Summaries will be provided to the funders of the study and results will be published in open-access journals.

Patient and public involvement
Patients are involved in the design and conduction of this trial. Priority of the research question, outcome measures and recruitment methods were discussed with patients during the initial planning stage. Patients have stated an uneventful postoperative course as a very notable feature, and every possible intervention contributing to lower postoperative morbidity was rated to be of great importance.

The chairman of one of Germany’s largest patient self-help groups concerning minimally invasive surgery (SHG Frankfurt Sachsenhausen) will be a member of the data safety and monitoring board as a patient representative. Therefore, this study will continue to take the patient’s perspective into account.

Modification of the protocol
The current protocol version (1.2) will be used during trial initiation. In case of protocol amendments, these will be submitted to the relevant ethics committees for approval.

Author affiliations
1Department of General, Visceral and Transplantation Surgery, Universitätsklinikum Heidelberg, Heidelberg, Germany
2Study Center of the German Society of Surgery, Heidelberg, Germany
3Institute of Medical Biometry and Informatics, Universitätsklinikum Heidelberg, Heidelberg, Germany
4Department of General, Visceral and Tumor and Transplantation Surgery, University Hospital Cologne, Köln, Germany
5Department of General, Visceral and Transplantation Surgery, Johannes Gutenberg University Hospital Mainz, Mainz, Germany
6Department of Visceral, Thoracic and Vascular Surgery, Universitätsklinikum Leipzig, Leipzig, Germany
7Department of General and Visceral Surgery, University Hospital Ulm, Ulm, Germany
8Department of Visceral and Transplantation Surgery, University Hospital Zurich, Zurich, Switzerland
9Department of Surgery, University Medical Center Schleswig Holstein Lübeck Campus, Lübeck, Germany
10Department of General, Visceral, Thoracic and Vascular Surgery, Klinikum Sudstadt Rostock, Rostock, Germany
11Department of General and Visceral Surgery, Klinikum Chemnitz gGmbH, Chemnitz, Germany
12Department of Digestive Surgery, Geneva University Hospitals, Geneva, Switzerland
13Department of Surgery, University Hospital Munich, München, Germany
14Department of General, Visceral, Transplant, Vascular and Pediatric Surgery, Central Würzburg Hospital, Würzburg, Germany
15Department of Visceral, Thoracic and Vascular Surgery, Technische Universität Dresden, Dresden, Germany
16Department of Surgery, Kantonsklinik Frauenfeld, Frauenfeld, Switzerland
17Department of General, Visceral and Transplantation Surgery, Klinikum Chemnitz gGmbH, Chemnitz, Germany
18Department of Digestive Surgery, Geneva University Hospitals, Geneva, Switzerland
19Department of Surgery, University Hospital Munich, München, Germany
20Department of General, Visceral, Transplant, Vascular and Pediatric Surgery, Central Würzburg Hospital, Würzburg, Germany
21Department of Visceral, Thoracic and Vascular Surgery, Technische Universität Dresden, Dresden, Germany
22Department of Surgery, Kantonsspital Frauenfeld, Frauenfeld, Switzerland

Acknowledgements
The authors gratefully acknowledge the study center of the German Society of Surgery (SDGC) in the Department of General, Visceral, and Transplantation Surgery at Heidelberg University医院 for its assistance in coordinating this RCT. We would also like to thank the other centres that have committed to participating in the trial.

Contributors FN and AS-F contributed equally as first authors. BPM-S, FN and AS-F developed the original concept of the trial and applied for funding. FN, AS-F, DH, CK, MF, SZ and BPM-S performed the design and methodology. BPM-S and FN recruited all participating trial centres. FN, AS-F, CK, MF, SZ and BPM-S performed initial statistical steps to develop the analysis plan. FN, AS-F, RK, SLV-A, ST, PP, AB and HN contributed to drafting the protocol. DH, CK, MF, SZ, BB, FB, CB, IG, SG, PG, CAG, JH, KL, LM, SM, DR, FS, DS, PP, TS and BPM-S contributed to the revision of the final protocol. All authors have read and approved of the final manuscript.

Funding The MEGA trial is funded by the Federal Ministry of Education and Research (BMBF), funding number 01KG2029. All trial aspects will be performed independently from the funding source, including trial design and conduction, analysis and interpretation of data, as well as submission of the report for publication.

Disclaimer The funder does not have any influence in study design or collection, management, analysis and interpretation of data.

Competing interests The authors declare that they have no conflicts of interest or relevant financial ties to disclose. FN reports support for courses and travel from Johnson & Johnson, Medtronic, Intuitive Surgical, Cambridge Medical Robotics and KARL STORZ as well as consultancy fees from KARL STORZ.

Patient and public involvement
Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
David Hausmann http://orcid.org/0000-0002-0571-4710
Sophia Lara Vogel-Adigozalov http://orcid.org/0000-0002-6100-2371
Benjamin Babic http://orcid.org/0000-0003-0313-6862
Pascal Protob http://orcid.org/0000-0002-0895-4015
Beat Peter Müller-Stich http://orcid.org/0000-0002-8552-8538

REFERENCES


